---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000033"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:08:35.051758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel Q1 revenue up 26% to $58.8M, net income $8.7M; reaffirms FY2026 guidance

## Summary
- Q1 total revenues $58.8M (net product sales $54.9M, contract $3.9M), up 26% YoY.
- Net income $8.7M ($0.44 diluted EPS) vs. $11.4M ($0.63 diluted) in Q1 2025.
- TAVALISSE sales $37.3M (+31%), GAVRETO $9.6M (+7%), REZLIDHIA $8.0M (+31%).
- Eli Lilly to terminate ocadusertib collaboration effective June 15, 2026.
- Restructured $40M MidCap revolver; repaid $40M term loan, drew $8M on new facility.

## SEC filing metadata
- accession: 0001034842-26-000033
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/0001034842-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/rigl-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000033
- JSON: https://secwatch.observer/filing/0001034842-26-000033.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000033.txt

## Source-grounded claims
- claim_id: 625ba2040d28b86e010c70e285664aa8b28b92f6
  claim: RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2026 results: revenue $58.8 million, net income $8.7 million of net income.
  evidence_excerpt: of any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- Rigel Reports First Quarter 2026 Financial Results • First quarter 2026 total revenues of $58.8 million , including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million • Generated $8.7 million of net income in the first quarter of 2026 • On
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/0001034842-26-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.